Saturday 17 October 2026 Export TRVN’s income statement to Excel — free account

Trevena, Inc.

TRVN Healthcare Biotechnology

Revenue growth for three consecutive years, operating cash flow growth for three.

0.00 0.07 −100.00%

Follow TRVN

Alert me

Market cap: $1.8M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: n/a
Altman Z: −22.13
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.35%

Capital & Financial Ratios $m

Market Cap 1.81

Revenue 0.55

Net Income (34.04)

Free Cash Flow (27.09)

Net Debt 19.13

Current Ratio 2.42

Debt/Equity (1.41)

P/E ratio 0.00

Fwd P/E (0.07)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 60.50%

Next Y EPS Growth 36.40%

Next Y revenue growth (79.90%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 59.66%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	67	38	33	14
Receivables	—	—	—	—
Inventory	2	1	—	—
Other	—	—	—	—
	71	41	35	15

	2021	2022	2023	Q'24
Payables	5	2	2	1
ST’ Debt	—	—	—	1
Other	—	—	—	—
	9	9	8	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	(11.43%)	0.60%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	0	—	—
’23	0	3	0	—	3
’22	0	—	—	0	—
’21	0	0	0	0	1
’20	—	—	3	0	3
’19	—	—	—	0	0
’18	—	3	3	0	6

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	(5)	—	—
’23	(11)	(7)	(9)	(6)	(33)
’22	(18)	(12)	(11)	(11)	(51)
’21	(14)	(12)	(11)	(13)	(50)
’20	(6)	(5)	(3)	(7)	(21)
’19	(8)	(3)	(6)	(7)	(24)
’18	(10)	(5)	(4)	(6)	(25)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(7)	(5)	—	—
’23	(11)	(7)	(9)	(6)	(33)
’22	(18)	(12)	(11)	(11)	(52)
’21	(14)	(12)	(11)	(13)	(50)
’20	(6)	(5)	(3)	(7)	(21)
’19	(8)	(3)	(6)	(7)	(24)
’18	(11)	(5)	(4)	(5)	(26)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(9.00)	(5.75)	(5.79)	—	—
’23	(20.25)	(17.25)	(14.25)	(26.50)	(79.00)
’22	(62.50)	(56.25)	(56.25)	(18.25)	(189.75)
’21	(37.50)	(56.25)	(50.00)	(50.00)	(200.00)
’20	(37.50)	(37.50)	(25.00)	(50.00)	(143.75)
’19	(37.50)	(31.25)	(56.25)	(43.75)	(168.75)
’18	(87.50)	(81.25)	(37.50)	(62.50)	(262.50)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	2,350.00	843.75	238.94	268.13	287.50	350.00	32.50	12.71	Analyst estimates 2024–2026 Powerpack
	High	—	—	6,568.56	5,000.00	2,236.44	1,250.00	2,300.00	1,937.50	402.19	82.00
People
People	Employees	—	—	72	51	29	24	25	43	35	23
	Revenue/emp, $m	—	—	0.05	0.00	0.20	0.00	0.12	0.01	(0.01)	0.14
Income, $m
Income, $m	Revenue	—	—	4	—	6	0	3	1	—	3
	Gross margin, %	—	—	100.00	0.00	100.00	100.00	94.07	(68.25)	822.01	46.56
	EBT	—	—	(103)	(72)	(30)	(25)	(29)	(52)	(54)	(40)
	EBT margin, %	—	—	(2,746.51)	0.00	(524.06)	(80,229.03)	(947.18)	(9,098.41)	12,839.71	(1,289.25)
	Net income	—	—	(103)	(72)	(31)	(25)	(29)	(52)	(54)	(40)
	Depreciation	—	—	2	1	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	44.75	0.00	48.70	0.21	15.03	2.17	(1.48)	6.13
	Earnings	—	—	(1,231.25)	(756.25)	(262.50)	(168.75)	(143.75)	(200.00)	(189.75)	(79.00)
	Cash flow	—	—	(1,092.53)	(749.26)	(215.59)	(161.33)	(104.77)	(192.18)	(181.96)	(64.85)
	Capex	—	—	(7.22)	(36.75)	(1.44)	0.00	(0.13)	(0.06)	(0.10)	(0.08)
	Free cash flow	—	—	(1,099.75)	(786.01)	(217.03)	(161.33)	(104.90)	(192.24)	(182.06)	(64.93)
	Book value	—	—	937.72	364.17	352.81	205.03	509.64	247.43	55.14	(15.03)
	Shares, m	—	—	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	42.95	—	4.16	13.38	81.97	167.71	0.00	3.01
	P/B	—	—	4.10	—	0.76	2.56	2.62	1.47	0.69	0.00
	EV/Sales	—	—	30.64	—	(1.64)	9.39	51.48	62.21	31.43	2.63
	EV/FCF	—	—	(2.49)	—	0.49	(2.27)	(8.00)	(0.70)	0.26	(0.25)
Cash, $m
Cash, $m	Operating cash flow	—	—	(92)	(71)	(25)	(24)	(21)	(50)	(51)	(33)
	Capex	—	—	(1)	(3)	0	—	0	0	0	0
	Free cash flow	—	—	(92)	(75)	(26)	(24)	(21)	(50)	(52)	(33)
Balance, $m
Balance, $m	Working capital	—	—	90	49	45	28	102	62	32	28
	Total debt	—	—	18	28	17	13	7	6	13	31
	Net debt	—	—	(92)	(38)	(44)	(23)	(102)	(61)	(25)	(2)
	Shareholders’ equity	—	—	79	35	42	30	104	65	16	(8)
Returns, %
Returns, %	ROA	—	—	(71.03)	(76.71)	(44.13)	(43.72)	(33.62)	(49.64)	(83.34)	(90.25)
	ROIC	—	—	0.00	0.00	0.00	(233.52)	(1,043.50)	(808.30)	0.00	0.00
	ROE	—	—	(92.91)	(126.95)	(80.84)	(69.47)	(43.79)	(61.16)	(133.79)	(1,014.57)

Negative figures in brackets.

value withheld pending a data check

All 10 years →

Fiscal years to Dec 2023 · latest quarter Sep 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLSDQ Clearside Biomedical, Inc.	$2.2M	— (loss-making)	— (loss-making)	−80.64% (below 0%: shrinking)	n/m	+8.15% (above 0%: growing)	100.00%	(3,502.49%)	Compare
BRTX Biorestorative Therapies, Inc.	$2.0M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)	Compare
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%	Compare
OGEN Oragenics, Inc.	$2.0M	0.4×	— (loss-making)	−75.33% (below 0%: shrinking)	n/m	−66.37% (below 0%: shrinking)	100.00%	0.00%	Compare
SILO Silo Pharma, Inc.	$1.9M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%	Compare
GNPX GENPREX	$1.9M	0.0×	—	—	n/m	−32.98% (below 0%: shrinking)	0.00%	0.00%	Compare
TRVN Trevena, Inc.	$1.8M	— (loss-making)	— (loss-making)	+57.22% (above 0%: growing)	n/m	+49.55% (above 0%: growing)	59.72%	(1,970.67%)
NEXI NexImmune, Inc.	$1.6M	— (loss-making)	—	—	n/m	+66.38% (above 0%: growing)	0.00%	0.00%	Compare
ITRMF Iterum Therapeutics PLC	$1.6M	— (loss-making)	— (loss-making)	+110.81% (above 0%: growing)	n/m	−179.15% (below 0%: shrinking)	94.87%	(1,982.31%)	Compare
Median of peers	$1.9M	—	—	−7.20%	—	−34.12%	34.05%	0.00%